Evaluating the Neuroprotective Effects of Caplacizumab in Thrombotic Thrombocytopenic Purpura with Quantitative MRI and CT

Motivation: Thrombotic Thrombocytopenic Purpura patients suffer from high risk of cognitive related complications post-remission that can decrease quality-of-life and in some cases death. Goal(s): We investigate a new treatment drug Caplacizumab to determine whether it can reduce neurocognitive burden. Approach: We use quantitative MRI and CT-perfusion to investigate patients that have received Caplacizumab to patients that have not. MRI and CT data look at a variety of different metrics to investigate brain health. Results: Preliminary results from CT-perfusion indicate better blood brain barrier recovery in Caplacizumab group, which may decrease cognitive burden. MRI results show significant decrease of myelin in patients without Caplacizumab. Impact: The results of this study can open the door for a new treatment for Thrombotic Thrombocytopenic Purpura patients that may ensure they do not suffer from cognitive decline or cerebrovascular disease related death.